Vincerx Pharma
Transforming Cancer Care via a Next Generation Bioconjugation Platform
Key Highlights
- Cancer is on the rise, as is the bar for treatments: We have yet to realize the full promise of precision oncology and provide patients with broadly applicable, safe, well-tolerated, curative treatments. Antibody Drug Conjugates (ADCs) offered initial promise to fill this need but many on the market are accompanied by Black Box warnings due to severe dose-limiting side effects. Vincerx is on a mission to create optimized ADC treatments. Vincerx’s clinical-stage pipeline of small-molecule drug conjugates (SMDCs) and ADCs are designed to precisely target and accumulate in tumor cells to drive efficacy, while protecting surrounding healthy tissue, and ultimately delivery cancer patients the gold medal medicines they deserve.
- Next generation bioconjugation platform: Vincerx’s VersAptx bioconjugation platform is revolutionizing cancer treatment by significantly improving the efficacy of marketed ADCs. With compelling data showcasing a 20-fold improvement in tumor toxicity over existing therapies such as TRODELVY and ENHERTU in in vitro tumor models, VersAptx holds the promise of unlocking new levels of efficacy and safety in cancer treatment.
- Key events for 2024:
- Presenting additional Phase 1 data for first in class SMDC, VIP236, being evaluated for multiple solid tumors in Q3 2024
- Presenting additional Phase 1 data for best-in-class ADC, VIP943, in Q4 2024
- Presenting additional dose-escalation data with NIH evaluating enitociclib, a novel CDK9 inhibitor, in a Phase 1 combination study for peripheral T cell lymphoma and double-hit diffuse large B cell lymphoma in June 2024